These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

199 related items for PubMed ID: 9326425

  • 21. Prophylaxis of cytomegalovirus infection in liver transplantation: a randomized trial comparing a combination of ganciclovir and acyclovir to acyclovir. NIDDK Liver Transplantation Database.
    Badley AD, Seaberg EC, Porayko MK, Wiesner RH, Keating MR, Wilhelm MP, Walker RC, Patel R, Marshall WF, DeBernardi M, Zetterman R, Steers JL, Paya CV.
    Transplantation; 1997 Jul 15; 64(1):66-73. PubMed ID: 9233703
    [Abstract] [Full Text] [Related]

  • 22. Ganciclovir prophylaxis to prevent CMV disease in kidney recipients undergoing anti-lymphocyte globulin treatment for acute rejection.
    Dickenmann MJ, Kabulbayev K, Steiger J, Cathomas G, Reusser P, Tamm M.
    Clin Microbiol Infect; 2004 Apr 15; 10(4):337-9. PubMed ID: 15059125
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Prospective comparison of valacyclovir and oral ganciclovir for prevention of cytomegalovirus disease in high-risk renal transplant recipients.
    Reischig T, Opatrný K, Treska V, Mares J, Jindra P, Svecová M.
    Kidney Blood Press Res; 2005 Apr 15; 28(4):218-25. PubMed ID: 16043964
    [Abstract] [Full Text] [Related]

  • 25. Combined antiviral and immunoglobulin therapy as prophylaxis against cytomegalovirus infection after heart transplantation.
    Valenza M, Czer LS, Pan SH, Aleksic I, Freimark D, Harasty DA, Admon D, Barath P, Blanche C, Trento A.
    J Heart Lung Transplant; 1995 Apr 15; 14(4):659-65. PubMed ID: 7578172
    [Abstract] [Full Text] [Related]

  • 26. Prophylaxis of cytomegalovirus disease with ganciclovir or anti-CMV immunoglobulin in renal transplant recipients who receive antilymphocytic antibodies as induction therapy.
    Morales E, Andrés A, González E, Herrero JC, Muñoz MA, Ortiz M, Espejo B, Lumbreras C, Morales JM, Aguado JM.
    Transplant Proc; 2002 Feb 15; 34(1):73-4. PubMed ID: 11959191
    [No Abstract] [Full Text] [Related]

  • 27. A prospective randomized study of acyclovir versus ganciclovir plus human immune globulin prophylaxis of cytomegalovirus infection after solid organ transplantation.
    Dunn DL, Gillingham KJ, Kramer MA, Schmidt WJ, Erice A, Balfour HH, Gores PF, Gruessner RW, Matas AJ, Payne WD.
    Transplantation; 1994 Mar 27; 57(6):876-84. PubMed ID: 8154035
    [Abstract] [Full Text] [Related]

  • 28. Evaluation of a Cytomegalovirus Prophylaxis Protocol in Cytomegalovirus-IgG Positive Renal Transplant Recipients (R+).
    Uslu A, Ari A, Simsek C, Olgut AI, Karatas M, Aykas A, Tercan IC, Tatar E.
    Transplant Proc; 2019 Sep 27; 51(7):2350-2354. PubMed ID: 31358453
    [Abstract] [Full Text] [Related]

  • 29. Low-dose valaciclovir prophylaxis against cytomegalovirus disease in renal transplant recipients.
    Reddy SP, Handa A, Tan L, Devaney A, Hughes D, Mason P, Friend PJ, Darby CR.
    Transpl Int; 2003 Oct 27; 16(10):726-9. PubMed ID: 12827230
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Early ganciclovir therapy effectively controls viremia and avoids the need for cytomegalovirus (CMV) prophylaxis in renal transplant patients with cytomegalovirus antigenemia.
    Gotti E, Suter F, Baruzzo S, Perani V, Moioli F, Remuzzi G.
    Clin Transplant; 1996 Dec 27; 10(6 Pt 1):550-5. PubMed ID: 8996777
    [Abstract] [Full Text] [Related]

  • 32. A comparative randomised study of valacyclovir vs. oral ganciclovir for cytomegalovirus prophylaxis in renal transplant recipients.
    Pavlopoulou ID, Syriopoulou VP, Chelioti H, Daikos GL, Stamatiades D, Kostakis A, Boletis JN.
    Clin Microbiol Infect; 2005 Sep 27; 11(9):736-43. PubMed ID: 16104989
    [Abstract] [Full Text] [Related]

  • 33. Costs and outcomes of prolonged cytomegalovirus prophylaxis to cover the enhanced immunosuppression phase following lung transplantation.
    Gerbase MW, Dubois D, Rothmeier C, Spiliopoulos A, Wunderli W, Nicod LP.
    Chest; 1999 Nov 27; 116(5):1265-72. PubMed ID: 10559085
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Cytomegalovirus disease recurrence after ganciclovir treatment in kidney and kidney-pancreas transplant recipients.
    Humar A, Uknis M, Carlone-Jambor C, Gruessner RW, Dunn DL, Matas A.
    Transplantation; 1999 Jan 15; 67(1):94-7. PubMed ID: 9921803
    [Abstract] [Full Text] [Related]

  • 36. Comparison of combined prophylaxis of cytomegalovirus hyperimmune globulin plus ganciclovir versus cytomegalovirus hyperimmune globulin alone in high-risk heart transplant recipients.
    Bonaros NE, Kocher A, Dunkler D, Grimm M, Zuckermann A, Ankersmit J, Ehrlich M, Wolner E, Laufer G.
    Transplantation; 2004 Mar 27; 77(6):890-7. PubMed ID: 15077033
    [Abstract] [Full Text] [Related]

  • 37. Reduced incidence of Epstein-Barr virus-associated posttransplant lymphoproliferative disorder using preemptive antiviral therapy.
    Darenkov IA, Marcarelli MA, Basadonna GP, Friedman AL, Lorber KM, Howe JG, Crouch J, Bia MJ, Kliger AS, Lorber MI.
    Transplantation; 1997 Sep 27; 64(6):848-52. PubMed ID: 9326409
    [Abstract] [Full Text] [Related]

  • 38. The role of PCR in the diagnosis and management of CMV in solid organ recipients: what is the predictive value for the development of disease and should PCR be used to guide antiviral therapy?
    Abecassis MM, Koffron AJ, Kaplan B, Buckingham M, Muldoon JP, Cribbins AJ, Kaufman DB, Fryer JP, Stuart J, Stuart FP.
    Transplantation; 1997 Jan 27; 63(2):275-9. PubMed ID: 9020330
    [Abstract] [Full Text] [Related]

  • 39. Risk factors and impact of cytomegalovirus disease in simultaneous pancreas-kidney transplantation.
    Kaufman DB, Leventhal JR, Gallon LG, Parker MA, Koffron AJ, Fryer JP, Abecassis MM, Stuart FP.
    Transplantation; 2001 Dec 27; 72(12):1940-5. PubMed ID: 11773893
    [Abstract] [Full Text] [Related]

  • 40. Long-term oral ganciclovir prophylaxis for prevention of cytomegalovirus infection and disease in cytomegalovirus high-risk renal transplant recipients.
    Kletzmayr J, Kreuzwieser E, Watkins-Riedel T, Berlakovich G, Kovarik J, Klauser R.
    Transplantation; 2000 Oct 27; 70(8):1174-80. PubMed ID: 11063336
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.